Nkarta, Inc. NKTX
Nkarta, Inc. (Nasdaq: NKTX) is an immunology/inflammation drug developer. Its lead program, NKX019, is in Phase 2 for Autoimmune diseases (systemic sclerosis, myositis, lupus nephritis, primary membranous nephropathy, ANCA-associated vasculitis, rheumatoid arthritis).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| NKX019 | Lupus nephritis and primary membranous nephropathy (Ntrust-1) | cell therapy | Phase 2 |
| NKX019 | Systemic sclerosis, myositis, AAV, and rheumatoid arthritis (Ntrust-2) | cell therapy | Phase 2 |
| NKX019 | Myasthenia gravis (IST at UC Irvine) | cell therapy | Phase 1 |
| NKX019 | Systemic lupus erythematosus (IST at Columbia) | cell therapy | Phase 1 |
| NKX101 | Not specified | cell therapy | Pre-clinical |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 immunology/inflammation companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.